Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04783753 · ClinicalTrials.gov registry record · Phase 1

Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects

A Phase 1 study, sponsored by Enanta Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
72
Enrollment target

NCT04783753: Completed Phase 1 study, sponsored by Enanta Pharmaceuticals.

NCT04783753 is a Phase 1 study that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04783753, a Phase 1 study, has completed, sponsored by Enanta Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
72 participants
Enrollment target

Study Summary

Non-randomized, 3-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of itraconazole, carbamazepine, or quinidine on the PK and safety of EDP-514 in healthy adult subjects.

Interventions

  • DRUG Itraconazole
  • DRUG EDP-514
  • DRUG Carbamazepin

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2020-11-05
Est. Completion 2021-07-09
Phase Phase 1
Enanta Pharmaceuticals

36 total trials

What the finished NCT04783753 record still lists

NCT04783753 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).

The record links to 0 conditions, and to 3 interventions - of which Itraconazole is the first listed.

NCT04783753 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04783753 about?

NCT04783753 is a clinical study titled "Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Quinidine in Healthy Subjects". Non-randomized, 3-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of itraconazole, carbamazepine, or quinidine on the PK and safety of EDP-514 in healthy adult subjects.

What is the current status of trial NCT04783753?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2020-11-05. Estimated completion is 2021-07-09.

What interventions are being tested in trial NCT04783753?

The interventions under investigation include: Itraconazole (DRUG), EDP-514 (DRUG), Carbamazepin (DRUG).

Who is sponsoring clinical trial NCT04783753?

This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04783753's enrollment target sits among peer trials

72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02359253 · 72 participants · NA

    Robot Aided Rehabilitation - Intervention

  • NCT02962661 · 72 participants · Phase 1

    Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

  • NCT03113643 · 72 participants · Phase 1

    SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • NCT03187535 · 72 participants · NA

    Effect of TEAS on PONV After Spinal Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04783753, the US trial registry maintained by the National Library of Medicine. NCT04783753 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.